Limb-Girdle Muscular Dystrophy
13
3
5
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.7%
1 terminated out of 13 trials
85.7%
-0.8% vs benchmark
15%
2 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (13)
Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
The Role of Muscle Ultrasound in Assessment of Sample of Patients With Limb-girdle Muscular Dystrophy
Weekly Steroids in Muscular Dystrophy
Molecular Analysis of Patients With Neuromuscular Disease
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy
MRI on Persons With Mutations in POMT2 Gene (LGMD2N)
MRI and Muscle Involvement in Patients With Mutations in GMPPB
Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
Study Evaluating MYO-029 in Adult Muscular Dystrophy